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• Autosomal recessive loss-of-function mutations in G6b-B (MPIG6B) cause 
congenital macrothrombocytopenia with focal myelofibrosis (cMTFM). 
• G6b-B has orthologous physiological functions in human and mice regulating 
megakaryocyte and platelet production and function. 
 
  








Unlike primary myelofibrosis (PMF) in adults, myelofibrosis in children is rare. Congenital 
(inherited) forms of myelofibrosis (cMF) have been described, but the underlying genetic 
mechanisms remain elusive.  Here we describe 4 families with autosomal recessive inherited 
macrothrombocytopenia with focal myelofibrosis due to germline loss-of-function mutations in 
the megakaryocyte-specific immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing 
receptor G6b-B (G6b, C6orf25 or MPIG6B).  Patients presented with a mild-to-moderate 
bleeding diathesis, macrothrombocytopenia, anemia, leukocytosis and atypical 
megakaryocytes associated with a distinctive, focal, perimegakaryocytic pattern of bone 
marrow fibrosis.  In addition to identifying the responsible gene, the description of G6b-B as 
the mutated protein potentially implicates aberrant G6b-B megakaryocytic signaling and 
activation in the pathogenesis of myelofibrosis.  Targeted insertion of human G6b in mice 
rescued the knockout phenotype and a copy number effect of human G6b-B expression was 
observed.  Homozygous knockin mice expressed 25% of human G6b-B and exhibited a 
marginal reduction in platelet count and mild alterations in platelet function; these phenotypes 
were more severe in heterozygous mice that expressed only 12% of human G6b-B.  This study 
establishes G6b-B as a critical regulator of platelet homeostasis in humans and mice.  In 
addition, the humanized G6b mouse will provide an invaluable tool for further investigating the 
physiological functions of human G6b-B as well as testing the efficacy of drugs targeting this 
receptor. 
  








Myelofibrosis in children is rare, and,  in children, is most commonly seen in association with 
acute megakaryoblastic leukemia.1  Other causes include acute lymphoblastic leukemia 
(ALL),2 Hodgkin lymphoma3, severe vitamin D or C deficiency,4,5 6 renal osteodystrophy7, 
osteopetrosis, hyperparathyroidism8, autoimmunity,9-11 and tuberculosis.12  The clinical, 
histologic and molecular features of pediatric myelofibrosis differ from primary myelofibrosis 
(PMF) in adults, which is typically due to somatic gain-of-function mutations in tyrosine kinase 
(TK) signaling pathways, including JAK2 V617F (50%), MPL W515K/L (5-10%) or CALR 
(35%);13,14  TK mutations are not typically present in pediatric myelofibrosis, particularly not in 
young children.15,1,16  Children with myelofibrosis have a heterogeneous phenotype with 
variable outcomes.  Some patients have spontaneous resolution,17,18 while others have an 
aggressive clinical course with progressive, sometimes fatal disease cured only by 
hematopoietic stem cell transplantation (HSCT)15,19-21. 
Congenital or inherited forms of myelofibrosis (cMF) are exceedingly rare with fewer than 50 
cases reported.15,18-26  Many cases occur in consanguineous families,15,19,25 suggesting that 
cMF can be inherited as a autosomal recessive Mendelian trait.  Genetic lesions have been 
identified in only a small minority of cases.  In some, concurrent single lineage cytopenias have 
been described.  For example, homozygous germline mutations in VPS45 cause neutropenia, 
neutrophil dysfunction, bone marrow (BM) fibrosis, progressive marrow failure and 
organomegaly.27,28  In some patients, fibrosis coexists with an intrinsic platelet disorder, such 
as gray platelet syndrome (GPS) to gain-of-function mutations in the Growth Factor Inhibitor 
1B (GFI1B) gene29 or biallelic mutations in neurobeachin-like 2 (NBEAL2).30-32  These 
phenotypes are quite distinct from most patients with cMF. 







Here we describe the clinical phenotype, distinctive histological features and biallelic loss-of-
function mutations in the megakaryocyte-specific immunoreceptor tyrosine-based inhibitor 
motif (ITIM)-containing receptor G6b-B (C6orf25 or MIPG6B, referred to as G6b) in four 
families with a clinically distinctive form of cMF associated with macrothrombocytopenia and 
focal myelofibrosis (cMTFM).  These phenotypes closely resemble those reported in G6b 
knockout (KO) and loss-of-function mice (Geer et al. co-submitted).33 A humanized G6b 
transgenic knockin (KI) mouse model establishes that human and mouse G6b-B perform 
orthologous  functions.  Mice homozygous for human G6b (G6bhu/hu) exhibit a mild platelet 
disorder attributed to reduced human G6b-B expression.  Reduced G6b-B expression in 
G6bhu/hu and heterozygous (G6bhu/-) mice also revealed novel regulatory roles of G6b-B with 











Materials and Methods 
Patients 
Families 1-3 consented to the Pediatric Myelodysplastic Syndrome and Bone Marrow Failure 
Registry (Boston Children’s Hospital, Protocol #10-02-0057).  Family 4 was consented to the 
Biomedical Research Centres/Units Inherited Diseases Genetic Evaluation-Bleeding and 
Platelet Disorders (BRIDGE-BPD) study (UK REC10/H0304/6).  All studies were conducted 
according to the Declaration of Helsinki.  
Hematological characterization and sample preparation 
Complete blood counts (CBC) and BM aspirates and biopsies were obtained on all clinically 
affected individuals; CBCs were obtained on other family members.  Whole blood or BM 
mononuclear cell DNA was extracted using the Qiagen Puregene Blood Kit (Qiagen, 
Germantown, MD).  BM aspirate and biopsy histology were prepared using standard clinical 
procedures.  Images were obtained with an Olympus BX43 microscope and DP25 digital 
camera and acquired with the Olympus CellSens Entry Imaging Software. 
Flow cytometry, immunohistochemistry, and immunoblotting 
Flow cytometry was performed on an BD Accuri C6 flow cytometer using methods and 
antibodies described in the Supplemental Methods. Immunohistochemical (IHC) staining for 
CD61 was done on Bouin’s-fixed, paraffin-embedded tissue sections using the Ventana 
Discovery XT automated platform.  A similar, custom automated IHC method was developed 
using a monoclonal antibody directed against the N-terminal ectodomain of G6b-B.33 Western 
blotting and immunoprecipitations were performed as previously described.34 
Linkage and sequencing analysis 
Affymetrix 6.0 SNP genotyping (QuintilesIMS, Research Triangle Park, NC) was performed on 







members of the index family (Family 1) and analyzed using a custom platform (Variant 
Explorer, K.S.-A. and K.M., unpublished).  Whole exome sequencing (WES) was performed in 
patients and immediate family members of Family 1 using the Illumina TrueSeq enrichment 
protocol.  Families 2 and 3 were sequenced using the Agilent SureSelect exome capture 
enrichment protocol.  Sequencing was performed on an Illumina Hiseq 2000/2500 with 100bp 
paired-end sequencing with an average depth of 40-200x (Macrogen, Rockville, MD).  FASTq 
sequences were processed and analyzed using the WuXi/NextCode platform (Cambridge, 
MA).  For individual 4-II-3, DNA library preparation, sequencing, variant calling and variant 
filtering were performed as described previously.35  Confirmatory Sanger sequencing was 
carried out on all patients and available family members as described in the Supplementary 
Methods.  
Mouse models 
Humanized G6b KI mice were generated as outlined in Figure S1 and supplementary material 
(Taconic Biosciences, Cologne, Germany).  G6b constitutive KO (G6b-/-) mouse models were 
generated as previously described.33  All mice were on a C57BL/6 background and procedures 
were undertaken with UK Home Office approval, in accordance with the Animals (Scientific 












Clinical and pathological characteristics 
We studied four consanguineous Arab families presenting with macrothrombocytopenia, 
anemia and myelofibrosis.  Family 1, from the United Arab Emirates (UAE), had three affected 
male siblings born to first cousin parents.  Affected individuals (Figure 1A and Table 1, 1-III-1, 
1-III-5, and 1-III-6) had macrothrombocytopenia with variably reduced platelet granularity, and 
microcytic anemia.  BM studies revealed clusters of atypical megakaryocytes with reticulin 
fibrosis that was most pronounced in proximity to the megakaryocytes.  Affected children had 
mild to moderate bleeding symptoms and required frequent platelet and occasional red cell 
transfusions; each affecte individual shared a homozygous human leukocyte antigen (HLA) 
haplotype and had congenital adrenal hyperplasia (CAH) due to 21-hydroxylase (CYP21A2) 
deficiency.  The children had three apparently unaffected cousins born to siblings of their 
parents.  One female cousin had CAH and shared the same homozygous HLA type as her 
affected cousins (Figure 1A and Table 1, 1-III-9,).  She was not thrombocytopenic and had 
only rare large platelets on her peripheral blood smear (Figure 2C).  While being evaluated as 
a transplant donor for her cousins, she underwent multiple BM studies, the first of which 
showed several lymphoid aggregates with associated reticulin, but normal megakaryocytes.  
Follow-up BM studies (Figure 2F, I) were normal.  Given the lack of a sibling, unrelated or cord 
blood donor, persistent transfusion dependency and lack of response to immunomodulatory 
agents, patients 1-III-5 and 1-III-6 underwent successful matched related HSCTs with 1-III-9 
serving as the donor.  Both patients engrafted and are doing well foloowing HSCT.  The 
proband in this family, 1-III-1, was transplanted using a haploidentical approach from his 
mother, and eventually succumbed to transplant-related complications.15 







Family 2 (Figure 1) is from Saudi Arabia.  The proband (2-II-6), whose parents are first 
cousins, had transient thrombocytopenia at birth.  Thrombocytopenia recurred at 6-months of 
life and was associated with severe microcytic anemia unresponsive to iron therapy.  BM 
studies performed elsewhere at age 2-years were reported to be normal.  Severe 
thrombocytopenia and anemia persisted despite several courses of intravenous 
immunoglobulin and steroids.  A BM at age 3-years showed a hypercellular marrow with 
increased lymphocytes, and clustering of atypical megakaryocytes with focal reticulin fibrosis.  
The patient’s older brother (2-II-5) was found to be an HLA identical match, but was ineligible 
as a donor due to moderate macrothrombocytopenia.  BM studies are not available for this 
individual, though he is presumed to be clinically affected.  Given the lack of a suitable donor 
and their mild phenotype requiring only occasional platelet transfusions, both children continue 
to be monitored. 
The proband in Family 3 (Figure 1A, 3-II-4) is the daughter of first cousin consanguineous 
parents from the UAE.  She presented at 15-months of age with leukocytosis, severe 
microcytic anemia and macrothrombocytopenia.  Her clinical features were strikingly similar to 
the affected children in Family 1.  Her BM showed a mildly hypercellular marrow for her age 
with a relative myeloid hyperplasia and clusters of atypical megakaryocytes with associated 
reticulin fibrosis.  Although Family 1 and Family 3 are not known to be related, 3-II-4 also has 
CAH and shares the same homozygous HLA type and CYP21A2 mutation as Family 1.  She is 
currently being followed without therapeutic intervention. JAK2, MPL and CALR mutation 
analysis  was negative in patients from Fimilies 1-3 (Table 1). 
The fourth family included an affected male and female sibling pair with 
macrothrombocytopenia, increased BM megakaryocytes, and grade II BM myelofibrosis 







(Figure 1A, 4-II-2, 4-II-3).  These children and an unaffected brother were born to first cousins 
of Arab descent.  The affected boy (4-II-2) had a more severe phenotype, including anemia 
with Howell-Jolly bodies, elevated fetal hemoglobin, dyserythropoiesis and 
dysmegakaryopoiesis.  Platelet surface expression of GPIbα, αIIb, α2 and GPIV were all 
unaltered, and there was a minor reduction in aggregation to ADP (data not shown). 
A detailed description of each case is included in the Supplemental Data. 
 
Linkage, mutational and protein expression analyses 
We performed Affymetrix SNP 6.0 genotyping on peripheral blood DNA from 10 individuals 
from Family 1 and assessed shared regions of homozygosity by descent in 1-III-5 and 1-III-6; 
1-III-9 was regarded as having an ambiguous phenotype. The major histocompatibility locus 
(MHC) on chromosome 6p, which, although not statistically significant, showed the strongest 
linkage (LOD=2.01, Figure 1B).  We focused on this region, because affected individuals in 
Family 1 and 3 had an identical homozygous HLA type and congenital adrenal hyperplasia 
(CAH) due to the identical CYP21A2 mutation (Table 1).  Furthermore, both affected 
individuals in Family 2 had a different, but homozygous, HLA haplotype; the CYP21A2 and 
HLA loci are located at 6p21.33 and 6p21.32-6p22.1, respectively (Figure 1B). 
We performed WES on nuclear families 1-3, and on individual 4-II-3 and interrogated the 
results for genes in which unambiguously affected members of each family carried a 
homozygous rare variant (allele frequency <0.005) within the candidate disease interval 
predicted to be functionally deleterious.  The only gene meeting these criteria was the 
megakaryocyte and platelet-specific receptor G6b (MPIG6B, C6orf25, referred to as G6b-B or 
G6b). 







G6b-B is a transmembrane receptor expressed on the surface of platelets and 
megakaryocytes.33,36-38  G6b-B has one extracellular immunoglobulin-like domain, a single 
transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
immunoreceptor tyrosine-based switch motif (ITSM) in its cytoplasmic tail.  Tyrosine 
phosphorylation of the ITIM and ITSM provides a docking site for the SRC homology 2 (SH2) 
domain-containing tyrosine phosphatases SHP1 (PTPN6) and SHP2 (PTPN11), which 
mediate downstream signalling.39,40  Murine KO and loss-of-function models of G6b result in a 
phenotype very similar to the patients, including macrothrombocytopenia, abnormal platelet 
function and the perimegakaryocytic pattern of bone marrow fibrosis present in patients (Geer 
at al. co-submitted).33  BM-derived mouse G6b-B-deficient megakaryocytes develop and 
proliferate normally in vitro, but failed to form highly branched proplatelets, suggesting that 
G6b-B regulates proplatelet formation, correlating with reduced platelet production.33  
Families 1 and 3 shared the same variant, a two base pair duplication bridging a splice donor 
site, NM_138272.2 c.61_61+1dup (p.?), and Family 2 had a unique homozygous frameshift 
mutation, c.149dup (p.Ala52GlyfsX128, Figure 1B).  These variants segregated with the 
phenotype in families 2 and 3; however, in family 1, individual 1-III-9, who had served as the 
HSCT donor for her cousins, genotyped as a homozygous mutant, despite having no overt 
clinical features of the disease other than rare giant platelets (Figure 2C).  In Family 4, we 
found a novel apparently homozygous missense variant c.469G>A (p.Gly157Arg, Figure 1B).  
The variant was also homozygous in the affected brother.  
Residues 143-163 encode the predicted transmembrane domain of G6b-B, and substituting a 
glycine with arginine would likely destabilize insertion of the receptor into the membrane.  
Expression of the p.Gly157Arg mutant protein was tested using transiently transfected DT40 







cells.  Introduction of the mutation caused a significant reduction in total G6b-B protein 
expression (Figure 1C), and surface expression was reduced by 84% by flow cytometry 
(Figures 1D, E).  A comparable reduction in expression was also observed in transiently 
transfected Chinese hamster ovary (CHO) cell line (data not shown). These data suggest that 
this rare missense variant is functionally significant. 
To further validate G6b variants as disease-causing, we evaluated G6b-B expression in BM 
biopsy specimens from affected patients and control samples by IHC using a monoclonal 
antibody specific to the ectodomain.  G6b-B was strongly and selectively expressed in 
megakaryocytes and platelets of control BM samples, but completely absent in 
megakaryocytes and platelets of the genotypically affected individuals from families 1-3 (Figure 
2J-2O).  BM biopsy samples were not available for patient 4-II-2 or 4-II-3 with the p.Gly157Arg 
mutation.  Thus, in combination with the complementary phenotype observed in G6b-/- mice,33 
the thrombocytopenia and BM myelofibrosis found in these patients is almost certainly due to 
reduced or absent expression of G6b-B.  
 
Expression of human G6b-B in G6bhu/hu mice 
To confirm that human and mouse G6b-B are orthologous, we generated a humanized G6b 
mouse model in which mouse G6b was replaced with its human counterpart (Figure S1 and 
Supplemental Methods).  Mice were born at expected Mendelian frequencies from 
heterozygous (G6bhu/+) breeding pairs (Table S1), and G6bhu/hu mice were healthy, fertile and 
survived >25 weeks without any overt developmental or growth anomalies.  Expression of 
human and mouse G6b-B was verified by flow cytometry (Figure S2) and western blotting 
(Figure 3A).  Expression of the human G6b-A splice isoform, which lacks the ITIM and ITSM, 







was also demonstrated using an isoform-specific antibody (Figure 3Ai, iv).  Both human 
isoforms were only expressed at 25% of normal human platelet levels.  The ratio of 
glycosylated (32 kDa) to unglycosylated (28 kDa) human G6b-B and -A was reduced from 3:2 
in human platelets to 2:3 in G6bhu/hu platelets (Figure 3B).   
The ability of human G6b-B to bind mouse Shp1 and Shp2 was also investigated in G6bhu/hu 
platelets (Figure 3C).  Similar amounts of human and mouse Shp1 and Shp2 co-
immunoprecipitated (co-IP’d) with human G6b-B from human and G6bhu/hu platelets under 
resting conditions (Figure 3Cii).  However, less Shp1 co-IP’d with human G6b-B from G6bhu/hu 
platelets compared with human platelets following collagen-stimulation, most likely reflecting 
differences in expression levels of Shp1 and Shp2 in human and mouse platelets (Figure 
S3).41,42  In contrast, comparable amounts of Shp2 co-IP’d with human G6b-B from collagen-
stimulated human and G6bhu/hu platelets. 
 
Human G6b-B functionally replaces mouse G6b-B 
Reduced human G6b-B expression resulted in an 21% reduction in platelet count and a 
marginal increase in platelet volume in G6bhu/hu mice (Table 2, Figure S4).  In contrast, 
complete ablation of G6b resulted in a >80% reduction in platelet count and >30% increase in 
platelet volume (Table 2), demonstrating that human G6b-B rescues the KO phenotype.  
Altered blood cell counts in G6b KO mice were independent of age (Figure S5).  Histological 
sections of spleens and femurs also demonstrated that expression of human G6b rescues the 
perimegakaryocytic pattern of bone marrow fibrosis previously identified in G6b KO mice 
(Figure S6).33  All other hematological parameters were normal in G6bhu/hu mice (Table 2).  







Blood counts were normal in G6b+/hu and G6b+/- mice (Table 2).33  Platelet surface levels of 
GPVI, CLEC-2, α2, αIIb and GPIbα were normal in platelets from G6bhu/hu mice (Figure S7). 
 
Reduced human G6b-B expression causes minor alterations in platelet function 
G6bhu/hu platelets provide a unique model to investigate the physiological consequence of 
reduced human G6b-B levels in platelets, without altered expression of other receptors 
identified in G6b-/- mice.33  No significant defects were observed in αIIbβ3-mediated adhesion 
and spreading of G6bhu/hu platelets on fibrinogen, in the presence or absence of thrombin 
(Figure S8).  Consistent with these findings, outside-in αIIbβ3 signaling was comparable 
between WT and G6bhu/hu platelets (Figure S9).  Bands corresponding to tyrosine 
phosphorylated mouse (45 kDa) and human (28-34 kDa doublet) G6b-B were observed in 
fibrinogen-adhered WT and G6bhu/hu platelets, respectively.  As G6bhu/hu mice do not express 
mouse G6b-B (Figure 3), the tyrosine phosphorylated band at 45 kDa is due to the presence of 
other co-migrating phosphorylated proteins.  
We next investigated (hemi)-ITAM receptor-mediated functional responses.  Unexpectedly, 
platelet aggregation was marginally reduced in response to low and intermediate 
concentrations (1-10 μg/ml) of the GPVI-specific agonist collagen-related peptide (CRP) 
(Figure 4A).  In contrast, CLEC-2-mediated platelet aggregation was marginally increased at 6 
μg/ml anti-CLEC-2 antibody (Figure 4A).  Platelet aggregation to thrombin, collagen, ADP and 
the TxA2 analogue U46619 were normal (Figure S10).  ATP secretion from dense granules 
was normal to all agonists tested (Figure 4A and S10), except for a minor increase at an 
intermediate dose of collagen.  These findings reveal minor alternations in platelet functional 







responses due to reduced human G6b-B expression that are likely of no physiological 
consequence. 
 
Altered G6bhu/hu platelet function does not affect thrombus formation or hemostasis 
We further investigated G6bhu/hu platelet functional responses under physiological flow 
conditions on different thrombogenic surfaces.  Platelet adhesion and thrombus formation were 
quantified by flowing anti-coagulated blood over: (1) collagen; (2) von Willebrand Factor-
binding protein (vWF-BP) and laminin; and (3) vWF-BP, laminin and the CLEC-2 agonist 
rhodocytin, for 3.5 minutes at 1,000 s-1.  Surface area coverage and morphological scores 
were used as measures of platelet adhesion and thrombus formation (Figure S11).  
Regression analysis of a cohort of WT mice (n=19) did not indicate that the 21% reduction in 
platelet counts in G6bhu/hu mice will affect any of the measured parameters (Figure S12).  The 
total surface area covered by G6bhu/hu platelets on collagen was unaltered compared with WT 
platelets (Figure 4B).  However, multilayer thrombus formation and contraction were both 
significantly increased, despite a minor reduction in αIIbβ3 activation and normal α-granule 
release, measured by immunostaining with JON/A and P-selectin antibodies, respectively 
(Figure 4B).  Altered thrombus morphology of G6bhu/hu platelets is most likely a reflection of the 
increased proportion of phosphatidylserine (PS)-positive procoagulant platelets, measured by 
Annexin V staining (Figure 4B). 
No difference in adhesion or platelet activation were observed when anti-coagulated blood 
from WT and G6bhu/hu mice was flowed over vWF-BP and laminin, or vWF-BP, laminin and 
rhodocytin (Figure S13).  Although some minor alterations in G6bhu/hu platelet activation were 
identified using this assay, expression of human G6b-B rescued the severe defects observed 







in G6b-/- platelets.  This rescue is likely due to a combination of increased platelet counts and 
normalized platelet reactivity.  Functional defects observed in G6bhu/hu platelets did not 
culminate in compromised hemostasis in mice, as assessed using the tail bleeding assay, 
whereas G6b-/- mice bled excessively, as previously reported (Figure 4C).33  
To determine the molecular basis of altered responses to CRP and anti-CLEC-2 antibody, we 
investigated tyrosine phosphorylation in WT and G6bhu/hu platelets.  The findings from 
aggregations studies were supported by a minor reduction in global tyrosine phosphorylation 
following CRP stimulation (Figure 5A).  A trend towards reduced SFK and Syk activities was 
identified, as measured by changes in autophosphorylation of Tyr418 and Tyr519/20 in the 
activation loops of SFKs and Syk, respectively, though this did not reach significance (Figure 
5A).  SFK-mediated phosphorylation of the ITAM-containing FcR γ-chain, which acts as a 
docking site for Syk to propagate signals downstream of GPVI, was also marginally reduced in 
CRP-stimulated G6bhu/hu platelets.  The opposite was observed in CLEC-2 activated platelets, 
in which global tyrosine phosphorylation, SFK and Syk activation were marginally increased in 
response to antibody-mediated cross-linking and activation of CLEC-2 (Figure 5B).  However, 
only Syk activation with 10 μg/ml anti-CLEC-2 antibody was significantly increased. 
 
Further reduction in human G6b-B expression exacerbates platelet defects 
To further investigate the threshold of human G6b-B expression required to rescue the G6b-/- 
phenotype, we generated human G6b hemizygous mice (G6bhu/-) by crossing G6bhu/hu mice 
with G6b-/- mice (Figure 6A).  G6bhu/- mice expressed only 12% of human G6b-B and -A 
compared with human platelets, and no mouse G6b-B (Figure 6A and S14A, B).  These 
expression levels produced an even greater reduction in platelet counts (29%) and a 







comparable increase in platelet volume (6-7%) compared with G6bhu/hu mice (Table 2).  This 
provides further evidence that human G6b-B dose dependently regulates platelet production.  
Surface receptor expression was normal in G6bhu/- platelets compared with WT platelets, 
except for CLEC-2, which was marginally reduced by 16% (Figure S14C).  Interestingly, 
platelet aggregation was further reduced in response to CRP and increased in response to 
antibody-mediated cross-linking of CLEC-2 (Figure 6B).  These findings demonstrate 
differential roles of G6b-B in regulating ITAM- and hemi-ITAM-containing receptor-mediated 
platelet activation at these expression levels.  No difference was observed upon activation of 
CLEC-2 using the snake toxin rhodocytin.  This likely reflects the tetravalent structure of 
rhodocytin that can elicit a more robust CLEC-2 activating signal, thus abrogating the mild 
phenotype observed with the bivalent anti-CLEC-2 antibody.   Thrombin-mediated aggregation 
of G6bhu/- platelets was normal and no significant defects in ATP secretion was observed for all 
agonists tested. 
  








Here we have described four families with a distinct phenotype of macrothrombocytopenia, 
microcytic anemia, variable leukocytosis and histologically characteristic megakaryocytic 
clustering, dysplasia and focal reticulin fibrosis in the BM presenting at young age.  We 
attribute this to homozygous loss-of-function mutations in G6b, the gene encoding G6b-B, a 
megakaryocytic/platelet-specific ITIM-containing receptor.  While this work was in preparation, 
another consanguineous Arab family with a similar phenotype was described with a 
homozygous predicted null mutation in G6b.26  These data firmly support the conclusion that 
recessive loss-of-function mutations in G6b result in the phenotype that we comprehensively 
describe and term congenital macrothrombocytopenia with cMTFM.  All of the clinically 
affected patients have a phenotype strikingly similar to a null mutation,33 or mutations that 
abolish ITIM/ITSM signaling,(Geer et al. co-submitted) in the murine orthologue.  
Concomitantly, we have demonstrated that the G6b KO phenotype can be rescued upon 
expression of human G6b.  
One apparently clinically unaffected individual, 1-III-9, without thrombocytopenia or anemia at 
the time of her evaluation as a transplant donor, also shares the G6b-B mutation; she did not 
have thrombocytopenia, bleeding symptoms, leukocytosis, anemia, or atypical 
megakaryocytes associated with fibrosis, but did have rare large platelets.  She did have 
transient BM lymphoid aggregates that are unusual for such a young child; these might be 
indicators of a primary BM disorder, but could equally be due to her CAH or other causes.  
Thus, it is likely that even genotypically similar patients might have varying expressivity or 
penetrance of the phenotype due to other modifying factors, including age, environment, and 
genotypes at other loci.  Indeed, for example, patient 2-II-5 came to medical attention only 







because of his more severely affected younger sibling, 2-II-6.  In addition to modifiers noted 
above, there are several possible explanations for the successful HSCT of the two siblings, 1-
III-5 and 1-III-6 from their cousin, 1-III-9, who shares the same homozygous mutant G6b 
genotype.  First, it is conceivable that the conditioning regimen alters the niche directly, which 
could impact the regulation of other components important in the regulation of megakaryocytic 
development, proplatelet and platelet formation.  Second, introduction of a new hematopoietic 
stem cell pool from the donor into the host with cMF could lead to immunological graft and host 
interactions between the stem cell compartment and the niche that could alter megakaryocytic 
development. 
The cMTFM phenotype underscores the importance of G6b-B signaling in normal 
megakaryocyte and platelet biology. Binding of Shp1 and Shp2 are essential for mediating 
signal transduced by G6b-B.  A mutant form of G6b-B that uncouples it from Shp1 and Shp2 
signaling phenocopies the G6b KO mouse model (Geer et al. co-submitted),33 and a tissue-
specific mouse model of combined Shp1 and Shp2 deficiency recapitulates multiple features of 
G6b KO animals,43 further indicating the essential nature of this signaling pathway to 
megakaryocyte function.  
The majority of reported patients with cMF have undergone HSCT as it was felt to be the only 
curative treatment optio.15 The histological resemblance to PMF in adults, which carries a risk 
of evolution to acute myeloid leukemia and a poor prognosis, may have encouraged providers 
to offer HSCT out of due caution, even in the absence of evidence for adverse outcomes when 
managed conservatively.  Indeed, in our series of 7 cases of patients with G6b mutations, 
three required HSCT for cytopenias, one was clinically unaffected, and three have been 
observed without ongoing clinical interventions.  The identification of a molecular therapeutic 







target—Shp1- and Shp2-dependent signal transduction—now offers the potential to 
circumvent the G6b-B deficiency in cMTFM and insights into the pathogenesis of other forms 
of primary and secondary myelofibrosis. 
The humanized G6b mouse provided compelling evidence of the analogous functions of 
human and mouse G6b-B.  The mild platelet phenotype, suggests human G6b-B interacts with 
the same ligands and signals in a similar manner to mouse G6b-B.  Reduced binding of human 
G6b-B to mouse Shp1 is most likely a reflection of the relative stoichiometries and binding 
affinities of Shp1 and Shp2 in mouse platelets.  Mouse platelets contain 6-fold higher levels of 
Shp2 than Shp1, whereas human platelets contain 2-fold more Shp1 than Shp2 (Figure 
S3).41,42  In addition, the binding affinity of tandem SH2 domains of human Shp2 with 
phosphorylated-G6b-B-ITIM-ITSM peptide is 100-fold greater than the binding affinity of 
tandem SH2 domains of Shp1.44  However, differences in the proportions of human G6b-B 
bound Shp1 and Shp2 in mouse versus human platelets are not likely to underlie the platelet 
defects described the humanized G6b mouse, as mouse G6b-B is predicted to bind the same 
ratios of Shp1 and Shp2.  Thus, platelet defects are more likely due to reduced human G6b-B 
expression. 
Despite the significant reduction in human G6b-B in G6bhu/hu and G6bhu/- mice, both mouse 
models exhibited only mild platelet phenotypes.  A large proportion of G6b-B is therefore not 
essential for maintenance of platelet homeostasis.  MKs from G6b-/- mice were previously 
shown to develop normally in vitro, but with significantly diminished proplatelet production 
capacity.33  Reduced platelet production in G6bhu/hu and G6bhu/- mice could therefore have 
been as a consequence of aberrant proplatelet formation, arising from reduced G6b-B 
expression in MKs.  The dose dependent nature of the reduction in platelet counts in these 







homozygous and heterozygous mice adds to the growing body of evidence of the vital role of 
G6b-B in regulating platelet production. 
The reduction in human G6b-B expression was predicted to lead to an increase in platelet 
reactivity to collagen.  Indeed, thrombus formation and contraction were significantly increased 
when whole blood was flowed over collagen, despite a marginal reduction in integrin αIIbβ3 
activation.  This can be explained by an enhancement in PS exposure and increased 
procoagulant activity of G6bhu/hu platelets, which is dependent upon PLCγ2-mediated Ca2+ flux 
and phosphatidylinositol 3-kinase signaling,45 highlighting these as potential downstream 
targets of Shp1 and Shp2.  The dose-dependent reduction in aggregation of G6bhu/hu and 
G6bhu/- platelets to CRP was however, counter-intuitive, suggesting G6b-B may act as both a 
positive and negative regulator of GPVI signaling, depending upon expression levels.  The 
candidate target of G6b-B-associated Shp1 and Shp2 is Syk tyrosine kinase that we previously 
showed is hyper-activated in G6b-B-deficient platelets.33  Syk contains multiple regulatory 
tyrosine phosphorylation sites that Shp1 and Shp2 may differentially dephosphorylate, 
depending upon the expression level of G6b-B, leading to either positive or negative effects on 
Syk activity.46 
This study establishes that human and mouse G6b-B perform the same physiological 
functions, and that deletion and loss-of-function mutations in G6b-B lead to megakaryocytic 
and myelofibrotic disorders in both species.  Validation of these analogous functions is 
essential to progress with exploring the role of G6b-B in various pathological conditions in 
humans and as a novel therapeutic drug target.  The humanized G6b-B mouse model 
described here provides an invaluable tool for investigating the efficacy and therapeutic 
potential of agents targeting human G6b-B in various disease conditions, including 







myeloproliferation and myelofibrosis, allowing for a greater understanding of the mechanism of 
action of these therapies. 
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Table 1.  Clinical and laboratory characteristics, treatments and outcomes of patients with congenital myelofibrosis. 
 








features JAK2 MPL CALR 
Therapy and 
response 
HLA   
A B C DRB1 DQB1 G6B genotype Outcome 
1-III-1 5 m M NA 6.0 20 66.0 NA microcytosis, 
anisopoikilocytosis, 
target cells, ovalocytes, 
large platelets 


















Deceased from SCT complications, 




M NA 6.9 16 NA NA anisopoikilocytosis, 
target cells, basophilic 
stippling, large platelets 





















6 years post-HSCT, engrafted, 
maturing trilineage hematopoiesis with 
no evidence of fibrosis. 
1-III-6 6 m M 13.79 8.7 19 68.0 NA microcytosis, 
anisopoikilocytosis, 
target cells, basophilic 
stippling, tear drops, 
frequent large platelets 
















4 years post-HSCT.  Slow platelet and 
RBC engraftment. Maturing trilineage 
hematopoiesis and no evidence of 
fibrosis, but platelets remain 
decreased, ~119-142 x109/L.  
1-III-9 2 y F 8.39 11.9 468 72.0 8.2 microcytosis CAH, mild 
iron 
deficiency 












Clinically unaffected, rare giant 
platelets 








80.5 NA anisopoikilocytosis, 
microcytosis, 

















Observation, stable disease 






















Observation, stable disease  
3-II-4 17 
m 




cells, ovalocytes, burr 

















Observation, stable disease 
4-II-2 18 
m 







ND Neg ND IVIG and 
steroid, no 
response 
ND ND ND ND ND c.469G>A 
p.Gly157Arg 
Observation, stable thrombocytopenia, 
supportive care with platelets 





None ND ND ND none ND ND ND ND ND c.469G>A 
p.Gly157Arg 
Observation, stable mild/moderate 
thrombocytopenia 
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1118 ± 209 1127 ± 219 884 ± 214*** 795 ± 187*** 206 ± 86*** 0.2 2 × 10-72 
Mean platelet 
volume (fl) 
5.8 ± 0.2 5.8 ± 0.2 6.1 ± 0.5*** 6.2 ± 0.4*** 7.8 ± 0.4*** 
-2 2 × 10-65 
Plateletcrit 
(%) 












7.5 ± 3.6 8.6 ± 2.3 7.4 ± 2.6 10.1 ± 6.1 13.1 ± 6.8*** 0.5 8 × 10-7 
Lymphocytes 
(109/L) 
6.2 ± 2.7 7.4 ± 2.0 6.9 ± 2.2 7.8 ± 3.7 11.8 ± 4.9*** 0.5 3× 10-11 
Monocytes 
(109/L) 
















All values expressed as mean ± SD. 
λ is the coefficient for the power transformation to minimize heteroscedasticity and non-normality 
P is the result of a one-way ANOVA on transformed data 
*** indicates P < 0.001 compared to WT with Dunnett’s post hoc test  









Figure 1.  cMTFM is due to mutations in G6b-B (G6b).  (A) Family pedigrees. Black arrows 
point to the probands in each family.  Double line indicates a consanguineous relationship.  
Ages are provided at the time of the initial evaluation of the youngest affected individual in the 
family.  For the deceased proband the age at diagnosis and age of death is listed.  (B) 
Ideograms showing cMTFM linkage region, the G6b (MPIG6B) locus and patient mutations.  
(C) Expression of p.Gly157Arg mutant in DT40 cells leads to (C) protein instability and (D, E) 
reduced expression on the surface of the cell (mean ± SEM, n=2).  pcDNA3 vector, grey; G6b-
B WT, green; G6b-B p.Gly157Arg, red, MFI, median fluorescence intensity, representative 
blots and histograms of two independent experiments. 
Figure 2.  Pathology of cMTFM.  Wright-Giemsa stained peripheral blood smears from (A) a 
normal control, (B) patient 3-II-4 and (C) the clinically unaffected, genotypically G6b-mutated 
individual 1-III-9. Note the large, hypogranular platelets (arrow) and RBC anisocytosis in 3-II-4 
and the rare giant platelet in 1-III-9 (arrow).  Serial histologic sections of a bone marrow 
biopsies from (D, G, J, M) a normal control individual, (E, H, K, N) 3-II-4, and (F, I, L, O) 1-III-9 
stained with (D-F) H&E, (G-I) Reticulin, (J-L) the megakaryocytic marker CD61, and (M-O) 
G6b-B.  Atypical megakaryocytes present in stellate clusters associated with increased 
reticulin staining are characteristic of cMTMF.  Staining for G6b-B is entirely negative in the 
megakaryocytes and platelets from 3-II-4 and 1-III-9. 
Figure 3.  Expression of G6b isoforms in humanized mouse model.  (A) WT, G6bhu/+, 
G6bhu/hu, human and G6b-/- washed platelet lysates (4 × 108/mL), were resolved by SDS-PAGE 
and custom antibodies used to detect mouse (m)G6b-B, human (h)G6b-B and hG6b-A.  
Expression was quantified and normalized to (i) WT or (ii, iii) human lysates, to show relevant 







expression levels in the mouse models.  (B) Quantification of glycosylated and unglycosylated 
human G6b-A and -B, data normalized to show percentage of total expression.  (C) hG6b-B 
was immunoprecipitated (IP) from basal and collagen activated G6bhu/hu and human washed 
platelet lysates (4 × 108/mL).  Co-IP of Shp1 and Shp2 was investigated by (i) SDS-PAGE 
before (ii) quantification and normalization to hG6b-B levels.  Quantification was completed 
using Licor Odyssey system. All data represented as mean ± SEM (n=3-4), *** P<0.001. 
Figure 4.  Minor alterations of G6bhu/hu platelet functional responses.  (A) Averaged 
aggregation and ATP release traces for washed platelets (2 × 108/mL) activated with indicated 
concentrations of CRP and anti-CLEC-2 antibody (Ab).  Area under the curve (AUC) 
quantification of (iii) platelet aggregation and (iv) ATP release (n=5-6 per condition, ** P<0.005 
and * P<0.05).  (B) Heparin-PPACK-fragmin anti-coagulated whole blood was flowed over 
glass coverslips coated with collagen immediately following collection.  (i) Brightfield images 
were immediately collected, followed by staining with PE-conjugated JON/A, FITC-conjugated 
P-selectin and Alexa647-conjugated Annexin V and fluorescence imaging.  Analysis 
quantifying (ii-vi) thrombus surface area coverage and morphological scores of adhered 
platelets, (n=5-6, *** P<0.001, ** P<0.005) and (vii-ix) surface area coverage of fluorescently 
labeled antibodies (n=5-6, *** P<0.001, * P<0.05).  (C) Total blood loss to body weight ratio of 
mice following excision of tail tip (n=12-16, *** P<0.001, ** P<0.005).  All data collection and 
analysis in panels B and C were completed blinded, mean ± SEM, scale bar: 10 μm 
Figure 5.  Altered tyrosine phosphorylation in response to GPVI and CLEC-2 agonists in 
G6bhu/hu platelets.  Representative blots (n=3) of lysates prepared from washed platelets (4 × 
108/mL) activated with indicated concentrations of (A) CRP (90 s, 10 μM lotrafiban, 10 μM 
indomethacin and 2 U/ml apyrase) or (B) CLEC-2 Ab (300 s, 10 μM lotrafiban) and probed with 







the indicated antibodies.  Src family kinase (SFK) phosphotyrosine (pTyr)418 and Syk 
pTyr519/20 were quantified using ImageJ and normalized to total tubulin and Syk reblots, 
respectively. 
Figure 6.  Further reduction in hG6b-B expression exacerbates observed phenotype.  (A) 
G6bhu/hu mice were crossed with G6b-/- mice to produce hemizygous (G6bhu/-) mice.  (ii) 
Representative blots and (iii) quantification of hG6b-B expression in the indicated genotypes 
(n=3).  (B) Average aggregation and ATP release traces and quantification of area under the 
curve (AUC) investigating functional response of G6bhu/- mouse washed platelets (2 × 108/mL) 
in response to indicated agonists (n=5-6, *** P<0.001, * P<0.05).  All bar graphs presented as 
mean ± SEM. 
 











































































































1 0 0 0 0
2 0 0 0 0
3 0 0 0 0


















For personal use only.on July 2, 2018. by guest  www.bloodjournal.orgFrom 
























CRP (µg/ml) 10 (iii)31











































































































































































































































































































































































































0 3 0 10
CLEC-2 Ab 
(µg/ml)



















































For personal use only.on July 2, 2018. by guest  www.bloodjournal.orgFrom 
For personal use only.on July 2, 2018. by guest  www.bloodjournal.orgFrom 
doi:10.1182/blood-2017-08-802769
Prepublished online June 13, 2018; 
 
 
Alexandra Mazharian, Mark D. Fleming and Yotis A. Senis
Pondarré, Rémi Favier, Gavin E. Jarvis, Kyriacos Markianos, Ernest Turro, Willem H Ouwehand, 
Johannes A. Eble, Klaus Schmitz-Abe, Esther A. Obeng, Michael Douglas, Kathleen Freson, Corinne
L. Calicchio, Silke Heising, Johanna P. van Geffen, Marijke J. E. Kuijpers, Johan W.M. Heemskerk, 
Inga Hofmann, Mitchell J. Geer, Timo Vögtle, Andrew Crispin, Dean R. Campagna, Alastair Barr, Monica
 
mutations in human G6b-B is rescued in humanized mice
Congenital macrothrombocytopenia with focal myelofibrosis due to
 
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml





digital object identifier (DOIs) and date of initial publication. 
indexed by PubMed from initial publication. Citations to Advance online articles must include 
final publication). Advance online articles are citable and establish publication priority; they are
appeared in the paper journal (edited, typeset versions may be posted when available prior to 
Advance online articles have been peer reviewed and accepted for publication but have not yet
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
For personal use only.on July 2, 2018. by guest  www.bloodjournal.orgFrom 
